Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26343991 | 0.84 | ELANE (0.53) | ELANEKMT2AGAAKDM4E | |
| SCHEMBL10180496 | 0.83 | ELANE (0.42) | ELANEKMT2AATMGAACES2 | |
| SCHEMBL24142228 | 0.82 | ELANE (0.41) | ELANEKMT2AATMGAACES2 | |
| SCHEMBL326469 | 0.81 | ELANE (0.44) | ELANEKIF11 | |
| SCHEMBL9872338 | 0.81 | LMNA (0.57) | ELANEKMT2AGAAALDH1A1CYP1A2 | |
| SCHEMBL27746984 | 0.81 | ELANE (0.48) | ELANEGAACES2CES1SMN1; SMN2 | |
| SCHEMBL10738024 | 0.81 | ELANE (0.56) | ELANEKMT2ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL8538472 | 0.81 | ELANE (0.44) | ELANEKMT2ACES2CES1KIF11 | |
| SCHEMBL13551942 | 0.81 | ELANE (0.70) | ELANEKMT2A | |
| SCHEMBL24361865 | 0.80 | ELANE (0.40) | ELANEKMT2AATMGAAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4668830-A | Process for the preparation of compounds containing a difluoromethylene or trifluoromethyl group | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1987-05-26 | — | — | US | claimed |
| US-20260070864-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING FLUOROALKYL GROUP | DAIKIN INDUSTRIES, LTD. (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4685127-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING FLUOROALKYL GROUP | Daikin Industries, Ltd. (JP) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024237156-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING FLUOROALKYL GROUP | ダイキン工業株式会社 | 2024-11-21 | — | — | WO | disclosed |
| CN-104112870-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2014-10-22 | — | — | CN | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-102484281-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2012-05-30 | — | — | CN | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2002099141-A9 | FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS | EPOCH BIOSCIENCES INC (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2002070469-A2 | SELECTIVE PDE3B INHIBITORS AND USE OF THE SAME IN THERAPY | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| EP-1173427-A1 | HYDROXAMIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000063197-A1 | HYDROXAMIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070864-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING FLUOROALKYL GROUP | AFF1, NAF1, AFF2 | ELANE 3463/4885KMT2A 2373/4885ATM 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.